Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q2 FY20 results · Jul–Sep 2019
Marksans Pharma reported revenue from operations of ₹256.40 crore (down 4.7% from Q2 FY19) and net profit of ₹25.97 crore (up 26.2% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 256.40 | 269.04 | −4.7% | 245.03 | +4.6% |
| Other income | 7.88 | (0.80) | Turned profit | 2.18 | +262.2% |
| Total income | 264.28 | 268.24 | −1.5% | 247.21 | +6.9% |
| Profit before tax | 33.66 | 27.72 | +21.4% | 27.61 | +21.9% |
| Net profit for the period | 25.97 | 20.57 | +26.2% | 22.48 | +15.5% |
| EPS, basic (₹) | 0.63 | 0.48 | +31.2% | 0.52 | +21.2% |
| Net margin (%) | 10.1 | 7.6 | 9.2 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 100.72 | 114.65 | −12.2% | 92.42 | +9.0% |
| Other income | 7.87 | 2.80 | +181.3% | 2.15 | +266.3% |
| Total income | 108.58 | 117.45 | −7.5% | 94.57 | +14.8% |
| Profit before tax | 15.53 | 16.54 | −6.1% | 7.91 | +96.3% |
| Net profit for the period | 11.86 | 12.34 | −3.9% | 5.66 | +109.8% |
| EPS, basic (₹) | 0.29 | 0.30 | −3.3% | 0.14 | +107.1% |
| Net margin (%) | 11.8 | 10.8 | 6.1 |
Consolidated
- Filed with BSE
- 18 Nov 2019, 12:41 IST
- Board meeting
- 12 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 Nov 2019, 12:41 IST
- Board meeting
- 12 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE